Article thumbnail

Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer Progression

By Li-Duan Tan, Yuan-Yuan Xu, Yue Yu, Xiao-Qing Li, Ying Chen and Yu-Mei Feng

Abstract

Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis. In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (P = 0.001), and also significantly correlated with HER2 level measured by ELISA (P = 1.06×10−11). Compared with ELISA method, the specificity and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-negative were higher than those with grade I–II (P = 0.004) and ER-positive (P = 0.033), respectively. Therefore, the novel dot blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast cancer progression in clinical situations

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3076436
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma.
  2. (1996). C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.
  3. (1992). C-erbB-2 protein in the sera of breast cancer patients.
  4. (2009). Cancer statistics,
  5. (2009). Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
  6. (2001). Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.
  7. (2011). Current technologies for HER2 testing in breast cancer. Crit Rev Oncol/Hematol;
  8. (1994). Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
  9. (2008). Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
  10. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene.
  11. (2006). Leary A
  12. (2010). Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
  13. (2004). Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
  14. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
  15. (2009). Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
  16. (2009). Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens.
  17. (2009). Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
  18. (1996). Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
  19. Seidman A (2002) HER2 testing and correlation with efficacy of trastuzumab therapy.
  20. (2006). Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.
  21. (2005). Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
  22. (2010). Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
  23. (1986). Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.
  24. (1994). Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer.
  25. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer.
  26. (2002). The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.
  27. (2003). Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.